Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Q/C Technologies reported a net loss of $11.3 million for the nine months ended September 30, 2026, driven by significant stock-based compensation and a $3.2 million impairment of a technology license. The company remains pre-revenue, with its accumulated deficit increasing to $155.9 million and total stockholders' equity declining to $16.1 million.
Nexentis Technologies Inc. reported a net loss of $12.7 million for the nine months ended September 30, 2026, significantly impacted by a $6.3 million goodwill impairment. Despite the year-to-date loss, the company achieved a net gain of $5.0 million in the third quarter of 2026, primarily driven by $7.1 million in financing income.
Canton Strategic Holdings, Inc. reported a significant net loss of $101.7 million for the nine months ended September 30, 2026, primarily driven by a $93.4 million unrealized loss on digital asset holdings. The company has transitioned its strategy toward a digital asset treasury and network validation, reporting its first $4.5 million in revenue from these operations during the period.
Range Impact, Inc. reported a net loss of $7.67 million for the nine months ended September 30, 2026, compared to a net income of $3.26 million in the prior year period. The shift was primarily driven by a $5.6 million gain on bargain purchase in 2025 that did not recur, alongside significant increases in accretion of asset retirement obligations and amortization of intangible assets.
MetaVia presented positive preclinical data at ObesityWeek® 2026 comparing its dual-receptor agonist DA-1726 against retatrutide in diet-induced obese mice. The study showed DA-1726 achieved comparable weight loss with less appetite suppression and superior glucose lowering, while significantly increasing hepatic FGF21 expression. The company plans to advance DA-1726 into a Phase 2 study for MetALD and ALD in the second half of 2027.
Kartoon Studios reported its Q3 2026 financial results, highlighting a cash and marketable securities position of $33.0 million. The company is shifting its strategy toward owning and commercializing high-value IP, including the upcoming launch of 'Hundred Acre Wood' on Amazon Prime and Walmart Marketplace in early 2027.
Term
Q3 2026
“We are building a fundamentally different Kartoon Studios, with ownership of great intellectual property at the center of our business and multiple ways to turn that creativity into lasting shareholder value. Our agreements with Amazon Prime and Walmart Marketplace bring that strategy to life, connecting entertainment with opportunities for families to discover and purchase products featuring our characters.”
Andy Heyward, Chairman and Chief Executive Officer
Nano Dimension Divestiture to QTREX Quantum Ltd. for $16M
Nano Dimension completed the divestiture of its subsidiary Global Inkjet Systems Limited (GIS) to QTREX Quantum Ltd. for $16 million in equity consideration. The deal includes QTREX ordinary shares, pre-funded warrants, and additional warrants, allowing Nano Dimension to retain exposure to GIS's future growth within the quantum computing infrastructure market.
iPower Inc. completed a fourth additional optional closing under its existing senior secured convertible note facility, issuing $2.0 million in principal amount of Series A Notes to an institutional investor. The company received gross proceeds of $1.88 million at a fixed conversion price of $1.488 per share, representing 120% of the recent Nasdaq closing price. To date, the company has sold $17.2 million in Series A Notes under the $30.0 million facility.
MA Specialty Credit Income Fund 10% Owner MA Eagle II Holdings Fund Sells $5M of Stock
MA Eagle II Holdings Fund, 10% Owner, sold 202,429 shares of MA Specialty Credit Income Fund at $24.70 a share, worth $5M in total on Nov 12, 2026. Shares held after the trade: 3,462,756 (-5.5%).
GXO Logistics is hosting its 2026 Investor Day at the New York Stock Exchange to present its long-term strategy, capital allocation framework, and 2030 financial targets. The company introduced a 2030 target of greater than 7% organic revenue CAGR and a preliminary 2027 outlook including above 5.5% organic revenue growth.
Santander Holdings USA, Inc. has commenced a cash tender offer to purchase any and all of its outstanding 4.100% Senior Notes due 2029. The aggregate principal amount of the notes outstanding is $300 million, and the offer is expected to expire on November 20, 2026.
Yan Chuang Group Inc. is a startup fintech company that has not yet generated revenue and reported a net loss of $26,715 for the quarter ended September 30, 2026. The company significantly increased its cash position to $626,089 through the issuance of common stock, though management expressed concerns regarding its ability to continue as a going concern without further capital.
WEN Acquisition Signs $1B M&A Deal with Our Next Energy Inc.
Wen Acquisition Corp (WENN), a SPAC, has entered into a definitive business combination agreement with Our Next Energy Inc. (ONE), a U.S.-based LFP battery manufacturer. The transaction values the combined company at a pro forma equity value of approximately $1 billion and is expected to provide up to $400 million in gross proceeds, including a $100 million PIPE. Upon closing in the first half of 2027, the combined company will be named Our Next Energy Holdings, Inc. and is expected to trade on Nasdaq under the ticker ONEE.
Value
$1B
Counterparty
Our Next Energy Inc.
“Over the last five years, LFP has grown from roughly 20% to 60% of the global battery market, yet China produces approximately 99% of the world’s LFP cells. We built ONE to close that gap with a secure American and allied supply chain. We believe our combination with Wen will give us a public platform to scale ONE into this $40B addressable market with access to growth capital as we scale our operations to meet rising demand.”
Mujeeb Ijaz, Founder and CEO of ONE
“ONE has done the hard part of building an American LFP cell and pack business, with factories operating and customers in markets that increasingly require domestic supply. With two operating factories, binding customer contracts, and federal policy appearing to move its way, ONE is positioned to lead the reshoring of critical battery manufacturing in the United States.”
Bitmine Immersion Technologies provided an operational update disclosing total crypto, cash, and marketable securities holdings of $11.8 billion. The company's treasury now includes 6.08 million ETH tokens, representing 4.97% of the total ETH supply, as part of its ongoing 'Alchemy of 5%' accumulation strategy.
Ainos reported Q3 2026 financial results with revenue increasing significantly to $642,889, driven by VELDONA licensing and AI Nose semiconductor programs. The company narrowed its GAAP net loss by 36% year-over-year and highlighted a subsequent $9 million follow-on order for its AI Nose systems.
“Our third-quarter results show progress in translating commercial agreements into revenue. Revenue reached $642,889, up 29,567% year over year, driven by VELDONA licensing and our AI Nose semiconductor program. We delivered 1,400 AI Nose systems under our initial $2.1 million agreement and received initial orders from another semiconductor customer.”
Eddy Tsai, Chairman, President and Chief Executive Officer
“Our Q3 2026 results demonstrate progress in both revenue generation and operating discipline. GAAP net loss improved 36% year over year while non-GAAP adjusted net loss improved 51%. GAAP gross margin increased to 83.4% from 78.0% in the third quarter of 2025, while non-GAAP gross margin increased to 83.6% from 78.0%, excluding share-based compensation and depreciation and amortization allocated to cost of revenue.”
Aptevo Therapeutics reported a net loss of $6.5 million for the quarter ended September 30, 2026, and a net loss attributable to common stockholders of $9.3 million after accounting for a $2.8 million deemed dividend. The company's cash position decreased significantly from $21.6 million at the end of 2025 to $8.3 million as of September 30, 2026, primarily due to $19.1 million used in operating activities.
John Marshall Bancorp M&A Deal with Eagle Financial Services, Inc.
John Marshall Bancorp and Eagle Financial Services announced that the Federal Reserve Bank of Richmond has approved the merger of their respective bank subsidiaries, Bank of Clarke and John Marshall Bank. The transaction, originally announced in September 2026, will create a combined community bank with approximately $4.3 billion in total assets. The deal remains subject to approval from the Virginia Bureau of Financial Institutions and shareholders of both companies.
Eagle Financial Services M&A Deal with John Marshall Bancorp, Inc.
Eagle Financial Services, Inc. (EFSI) and John Marshall Bancorp, Inc. (JMSB) announced that the Federal Reserve Bank of Richmond has approved the merger of Bank of Clarke into John Marshall Bank. The transaction, originally announced in September 2026, will create a combined community bank with approximately $4.3 billion in total assets. The deal remains subject to approval from the Virginia Bureau of Financial Institutions and shareholders of both companies at meetings scheduled for November 19, 2026.
Donegal Group Insider Donegal Mutual Insurance Co Buys $285K of Stock
Donegal Mutual Insurance Co bought 15,000 shares of Donegal Group Inc at $18.94 to $19.01 a share (average $18.98) in 2 transactions, worth $285K in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 14,472,628 (+0.1%).
Columbia Financial management will participate in investor meetings hosted by Piper Sandler on November 17 and 18, 2026. The company will discuss a presentation that will be made available on its Investor Relations website.
Rein Therapeutics announced preliminary blinded Phase 2 data from its RENEW trial evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF). The data showed that 33% of evaluable patients demonstrated improvement in forced vital capacity (FVC) at Week 12, with favorable safety and tolerability observed across the study population.
“As we continue to enroll patients in the study, today’s blinded look at the data shows encouraging lung function trends and a favorable safety and tolerability profile across the study population, reinforcing our confidence in the potential of LTI-03 to deliver a differentiated clinical and safety profile for patients with significant unmet need.”
Brian Windsor, Ph.D., President and Chief Executive Officer
CRH Finance DAC, a subsidiary of CRH plc, completed the issuance and sale of €750 million 4.250% Notes due 2033 and €750 million 4.625% Notes due 2038. The notes are fully guaranteed by CRH plc and were issued under a €10 billion Euro Medium Term Note Programme. Net proceeds are intended for general corporate purposes.
Canton Strategic Holdings reported its third quarter 2026 financial results, achieving its first positive Adjusted EBITDA of $0.6 million. Total revenue grew 104% sequentially to $3 million, driven by the first full quarter of Super Validator and locking-as-a-service operations. The company reported a net loss of $35.1 million, primarily reflecting non-cash items as it continues to scale its Canton Network strategy.
“We are proud to have achieved our first positive Adjusted EBITDA this quarter, a notable milestone as we mark the first year of operations since our launch in November 2025. With a full year under our belt as a publicly traded company operating our CC strategy, we remain focused on growth. Our Super Validator operations and locking-as-a-service offering allow us to support the Canton Network and its participants while also earning revenue that we can deploy for continued investment in the ecosystem and enhanced value for shareholders. With our operating cost base largely fixed and clear visibility to additional approved Super Validator weight, we believe the business is positioned for significant operating leverage and margin expansion.”
Mark Wendland, Chairman and Chief Executive Officer
Cycurion reported record quarterly revenue of $5.4 million for Q3 2026, a 40% increase year-over-year, driven by recent acquisitions and a return to growth in existing operations. Gross profit increased more than sevenfold to $1.9 million, while the company's operating loss narrowed by 35% to $3.0 million.
Term
Q3 2026
“Our third-quarter results demonstrate the momentum we are building at Cycurion. Higher-margin revenue translated into substantially more gross profit, and we narrowed our operating and adjusted EBITDA losses. We also returned to revenue growth in our existing operations while adding contributions from our acquisitions. We are encouraged by this progress and focused on carrying it forward.”
L. Kevin Kelly, Chairman and Chief Executive Officer
“We see a significant opportunity ahead. Our acquisitions have expanded our capabilities and customer reach, and our predictive intelligence strategy gives us more ways to help customers identify and address their most consequential threats. Our team, which includes veterans of the U.S. Intelligence Community and the private-sector cybersecurity industry, is focused on converting those opportunities into recurring revenue, stronger gross profit and continued progress toward profitability. We are building on a stronger operating foundation while maintaining expense discipline and working to improve operating cash flow.”
L. Kevin Kelly, Chairman and Chief Executive Officer
StablecoinX reported its third quarter 2026 financial results, highlighting a 666% sequential revenue increase to $0.48 million driven by its Decentralized Verifier Node (DVN) infrastructure. The company reported a GAAP net loss of $100.2 million, primarily due to non-cash warrant liability adjustments, while its ENA token treasury was valued at approximately $802 million at quarter-end.
Term
Q3 2026
“Our third quarter performance provided an initial indication of the value StablecoinX was built to deliver. Our verifier infrastructure doubled its cumulative verified volume to more than $6 billion in less than two months, which increased revenue nearly eightfold sequentially.”
Aptevo Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a business update on its clinical pipeline. The company highlighted a 79% remission rate for its lead candidate mipletamig in high-risk TP53-mutated AML patients, which is nearly double the historical benchmark for standard-of-care treatments.
“We are entering an exciting period for Aptevo, with growing clinical evidence that reinforces our confidence in mipletamig and meaningful progress across our broader pipeline. We are seeing strong clinical activity in patients with some of the most difficult-to-treat forms of AML, patients advancing to potentially curative stem cell transplantation, and important improvements in tolerability.”
Jeff Lamothe, President and Chief Executive Officer of Aptevo
“As we approach important clinical and development milestones, we believe Aptevo is increasingly well positioned to translate the strength of our science into meaningful opportunities for patients and long-term value for shareholders.”
Jeff Lamothe, President and Chief Executive Officer of Aptevo
Super League Enterprise, Inc. entered into a securities purchase agreement with accredited investors for a registered direct offering of 150,000 shares of common stock. The offering is priced at $4.00 per share and is expected to result in gross proceeds of approximately $600,000. The transaction is conducted under the company's existing shelf registration statement and is scheduled to close around November 16, 2026.
PT Freeport Indonesia (PTFI), a 48.76% owned subsidiary of Freeport-McMoRan, announced its intention to offer one or more series of U.S. Dollar denominated senior unsecured notes. The proceeds from the offering are intended to refinance existing indebtedness and for general corporate purposes. The notes will be included in Freeport-McMoRan's consolidated debt once issued.
Professional Diversity Network reported a total revenue of $3.44 million for the nine months ended September 30, 2026, a decrease from $4.61 million in the prior year. The company experienced a net loss of $5.98 million during this period, driven by significantly higher depreciation and amortization expenses and a decline in recruitment services revenue.
Larimar Therapeutics reported a net loss of $31.1 million for the third quarter of 2026, an improvement from the $47.7 million loss in the prior year period, primarily driven by a significant decrease in research and development expenses. The company strengthened its balance sheet through equity issuances, ending September 30, 2026, with $128.7 million in cash, cash equivalents, and marketable securities.